VI Brazilian consensus guidelines for detection of anti-cell autoantibodies on HEp-2 cells
Tóm tắt
The VI Brazilian Consensus on Autoantibodies against HEp-2 cells for determination of autoantibodies against cellular constituents on HEp-2 cells was held on September, 2019, in Fortaleza (CE, Brazil). The guidelines in this edition were formulated by the group of Brazilian experts discussing the classification of complex patterns, the classification of the nuclear discrete dots (few and multiple), the identification of the discrete fine speckled pattern (AC-4a) and improvements on the ANA report. Sixteen Brazilian researchers and experts from universities and clinical laboratories representing the various geographical regions of Brazil participated in the meeting. Four main topics were discussed: (1) How to classify patterns with fluorescence in more than one cell compartment considering three relevant categoris: composite patterns, mixed patterns and multiple patterns; (2) The splitting of the discrete nuclear dots pattern into the multiple discrete nuclear dots (AC-6) and few discrete nuclear dots (AC-7) patterns, respectively; (3) Inclusion of a novel nuclear pattern characterized by discrete fine speckled pattern highly associated with antibodies to SS-A/Ro60, classified as AC-4a. In addition, adjustments on the Brazilian Consensus nomenclature were implemented aiming to harmonize the designation of some patterns with the International Consensus on ANA Patterns (ICAP). Furthermore, the designations of the PCNA-like pattern (AC-13), CENP-F-like pattern (AC-14) and Topo I-like pattern (AC-29) were adjusted in accordance to ICAP. Finally, there was a recommendation for adjustment in the test report in order to address the status of nuclear envelope staining. For all topics, the aim was to establish specific guidelines for laboratories and clinicians. All recommendations were based on consensus among participants. All recommendations from the V Consensus were maintained and there was relevant progress in the BCA/HEp-2 guidelines and further harmonization with ICAP. The VI BCA/HEp-2 edition was successful in establishing important recommendations regarding the classification of complex patterns, in supporting the identification of a novel pattern within the AC-4 group and in the harmonization process with the ICAP terminology.
Tài liệu tham khảo
Cruvinel WDM, Andrade LEC, Von Mühlen CA, et al. V Brazilian consensus guidelines for detection of anti-cell autoantibodies on hep-2 cells. Adv Rheumatol. 2019;59(1):28. https://doi.org/10.1186/s42358-019-0069-5.
Chan EKL, Damoiseaux J, Carballo OG, et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015. Front Immunol. 2015. https://doi.org/10.3389/fimmu.2015.00412/abstract.
Andrade LEC, Klotz W, Herold M, et al. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med. 2018;56(10):1783–8.
Herold M, Klotz W, Andrade LEC et al. International Consensus on Antinuclear Antibody Patterns: defining negative results and reporting unidentified patterns. Clinical chemistry and laboratory medicine, 2018.
Francescantonio PLC, Cruvinel WD, Dellavance A, et al. IV Brazilian guidelines for autoantibodies on HEp-2 cells. Rev Bras Reumatol. 2014;54(1):44–50.
Francescantonio PLC, Andrade LEC, Cruvinel WDM, et al. III Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2: perspectiva histórica, controle de qualidade e associações clínicas. J Bras Patot Med Lab. 2009;45(3):185–99.
Dellavance A, Grabriel A Jr, Cintra AFU, et al. II Consenso Brasileiro de Fator Antinuclear em Células HEp-2. Rev Bras Reumatol. 2003;43(3):129–40.
Dellavance A, Gabriel A Jr, Nuccitelli B, et al. 3° Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2 (Fan). Recomendações para padronização do ensaio de pesquisa de autoanticorpos em células HEp-2, controle de qualidade e associações clínicas. Rev Bras Reumatol. 2009;49(2):89–109.
Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect Immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Annal Rheum Dis. 2019;78(7):879–89. https://doi.org/10.1136/annrheumdis-2018-214436.
Fusconi M, Cassani F, Govoni M, et al. Anti-nuclear antibodies of primary biliary cirrhosis recognize 78–92-kD and 96–100-kD proteins of nuclear bodies. Clin Exp Immunol. 1991;83(2):291–7.
Szostecki C, Krippner H, Penner E, Bautz FA. Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). Clin Exp Immunol. 1987;68(1):108–16.
Cozzani E, Drosera M, Riva S, Parodi A. Analysis of a multiple nuclear dots pattern in a large cohort of dermatological patients. Clin Lab. 2012;58(3–4):329–32.
Xie K, Lambie EJ, Snyder M. Nuclear dot antigens may specify transcriptional domains in the nucleus. Mol Cell Biol. 1993;13(10):6170–9.
Sternsdorf T, Guldner HH, Szostecki C, Grötzinger T, Will H. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol. 1995;42(2):257–68.
Züchner D, Sternsdorf T, Szostecki C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology. 1997;26(5):1123–30. https://doi.org/10.1002/hep.510260506.
Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60(6):1807–14.
Kimura Y, Sakai F, Nakano O, et al. The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem. 2002;277(23):20611–7.
Takahashi K, Yoshida N, Murakami N, et al. Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell. 2007;18(5):1701–9.
Granito A, Yang W-H, Muratori L, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(1):125–31.
Hu S-L, Zhao F-R, Hu Q, Chen W-X. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS ONE. 2014;9(7):e101916.
Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016;29(5):662–73.
Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients With polymyositis/dermatomyositis. Arthritis Res Therapy. 2012;14(2):R97.
Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Annal Rheum Dis. 2012;71(5):710–3.
Andrade LE, Tan EM, Chan EK. Immunocytochemical analysis of the coiled body in the cell cycle and during cell proliferation. Proc Natl Acad Sci United States of Am. 1993;90(5):1947–51.
Andrade LE, Chan EK, Raska I, et al. Human autoantibody to a novel protein of the nuclear coiled body: immunological characterization and cDNA cloning of p80-coilin. J Exp Med. 1991;173(6):1407–19.
Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nature Rev Neurosci. 2009;10(8):597–609.
Satoh M, Chan JYF, Ross SJ, et al. Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins. Arthritis Rheum. 2011;63(7):1972–8.
Fujimoto M, Kikuchi K, Tamaki T, et al. Distribution of anti-p80-coilin autoantibody in collagen diseases and various skin diseases. Br J Dermatol. 1997;137(6):916–20.
Onouchi H, Muro Y, Tomita Y. Clinical features and IgG subclass distribution of anti-p80 coilin antibodies. J Autoimmun. 1999;13(2):225–32.
Dellavance A, Alvarenga RR, Rodrigues SH, et al. Autoantibodies to 60kDa SS-A/Ro yield a specific nuclear myriad discrete fine speckled immunofluorescence pattern. J Immunol Methods. 2013;390(1–2):35–40.
Röber N, Dellavance A, Ingénito F, et al. Strong association of the myriad discrete speckled nuclear pattern with anti-SS-A/Ro60 antibodies: consensus experience of four international expert centers. Front Immunol. 2021;12: 730102. https://doi.org/10.3389/fimmu.2021.730102.
Northway JD, Tan EM. Differentiation of antinuclear antibodies giving speckled staining patterns in immunofluorescence. Clinic Immunol Immunopathol. 1972;1(1):140–54.
von Mühlen CA, Garcia-de la Torre I, Infantino M, et al. How to report the antinuclear antibodies (anti-cell antibodies) test HEp-2 cells: on cells guidelines from the ICAP initiative. Immunol Res. 2021;69(6):594–608. https://doi.org/10.1007/s12026-021-09233-0.